Giovannoni G, et al. Treatment outcomes of daclizumab in patients at high risk of transitioning to secondary progressive multiple sclerosis in DECIDE. EAN 2107, O2113.
Ocrelizumab bij relapsing en primair progressieve MS
jan 2017 | Multipele Sclerose